Top-News
  • Depot
  • Watchlist
  • Glocke
  • Handeln

    • Vanda Pharmaceuticals News

    4,24 € -0,47% -0,02 €
    08:30:43 Uhr Tradegate aktualisieren | Orderbuch | Mehr Kurse »
    WKN: A0JJT3
    ISIN: US9216591084
    US-Symbol: VNDA
    Typ: Aktie

    Vanda Pharmaceuticals News

    22.04.24 - PR Newswire
    Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation
    Vanda Pharmaceuticals Reacts to U.S. Supreme Court's Denial of its Petition in HETLIOZ® ANDA Litigation PR Newswire
    17.04.24 - PR Newswire
    Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan
    Vanda Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan PR Newswire
    17.04.24 - PR Newswire
    Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak
    Vanda Pharmaceuticals Confirms Rejection of Unsolicited Takeover Proposals from Future Pak PR Newswire
    02.04.24 - PR Newswire
    Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder
    Vanda Pharmaceuticals' Fanapt® (iloperidone) Receives U.S. FDA Approval for the Acute Treatment of Bipolar I Disorder PR Newswire
    27.03.24 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA PR Newswire
    25.03.24 - PR Newswire
    Thinking about buying stock in Intellicheck, Vanda Pharmaceuticals, Dave Inc, Invivyd, or Dream Finders Homes?
    Thinking about buying stock in Intellicheck, Vanda Pharmaceuticals, Dave Inc, Invivyd, or Dream Finders Homes? PR Newswire
    19.03.24 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA PR Newswire
    11.03.24 - PR Newswire
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA
    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceutical Inc. - VNDA PR Newswire
    06.03.24 - PR Newswire
    Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
    Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia PR Newswire
    23.02.24 - PR Newswire
    Thinking about buying stock in Maravai Lifesciences, Abercrombie & Fitch, elf Beauty, IONQ, or Vanda Pharmaceuticals?
    Thinking about buying stock in Maravai Lifesciences, Abercrombie & Fitch, elf Beauty, IONQ, or Vanda Pharmaceuticals? PR Newswire
    07.02.24 - PR Newswire
    Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
    Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results PR Newswire
    05.02.24 - PR Newswire
    Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia
    Vanda Pharmaceuticals Announces FDA Update for supplemental NDA for HETLIOZ® in the Treatment of Insomnia PR Newswire
    31.01.24 - PR Newswire
    Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024
    Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results on February 7, 2024 PR Newswire
    31.01.24 - PR Newswire
    Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis
    Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VTR-297 a Topical Antifungal Candidate for the Treatment of Onychomycosis PR Newswire
    30.01.24 - PR Newswire
    Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024
    Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024 PR Newswire
    29.01.24 - PR Newswire
    Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024
    Court Orders FDA to Resolve Vanda Pharmaceuticals' Jet Lag Hearing Request by March 5, 2024 PR Newswire
    25.01.24 - PR Newswire
    Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S.
    Vanda Pharmaceuticals Announces a U.S. Patent Allowance for PONVORY® (ponesimod) in the U.S. PR Newswire
    25.01.24 - PR Newswire
    Vanda Pharmaceuticals announces the publication of an article on "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized Placebo-Controlled Clinical Trial" in the Clinical Gastroenterology and Hepatology Journal
    Vanda Pharmaceuticals announces the publication of an article on "The Efficacy of Tradipitant in Patients with Diabetic and Idiopathic Gastroparesis in Phase III Randomized ...
    23.01.24 - PR Newswire
    Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S
    Vanda Pharmaceuticals Receives FDA Approval to Proceed with Investigational New Drug VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-...
    19.01.24 - PR Newswire
    Federal Court Allows Vanda Pharmaceuticals' Lawsuit to Proceed Against the U.S. Food and Drug Administration
    Federal Court Allows Vanda Pharmaceuticals' Lawsuit to Proceed Against the U.S. Food and Drug Administration PR Newswire

    Newssuche

    Videos

    newspaper
    09:30 Uhr +22,76%
    Technical Trading: S&P 500 Short Chance
    S&P 500 Short Typ: Turbo Open End WKN: NG8FUZ Hebel: 31 Laufzeit: OpenEnd Einstieg: Market ... Mehr »